Specialty code 1835P2201X · Sacramento, CA
NPI
1659725653
Since 2016
Specialty
Specialty code 1835P2201X
Code 1835P2201X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
6600 Bruceville Rd
Sacramento, CA, 95823
Phone (916) 525-4920
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$402K
2,308 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Hoa Phan prescribed most often to Medicare patients was Atorvastatin Calcium, with 209 prescriptions and refills. In total Hoa Phan wrote 2,308 Medicare prescriptions that cost $402K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-04.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 209 | 696 | 94 | $2,552 |
| Metformin Hcl Generic | 136 | 451 | 62 | $1,700 |
| Glipizide Generic | 134 | 438 | 67 | $1,613 |
| Metformin Hcl Er Metformin Hcl | 129 | 425 | 64 | $1,269 |
| Insulin Glargine-Yfgn Generic | 119 | 325 | 62 | $16K |
| Ozempic Semaglutide | 117 | 120 | 21 | $87K |
| Jardiance Empagliflozin | 116 | 383 | 52 | $66K |
| Lisinopril Generic | 108 | 357 | 50 | $1,313 |
| Victoza 2-Pak Liraglutide | 107 | 116 | 29 | $68K |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 104 | 314 | 52 | $2,685 |
| Losartan Potassium Generic | 101 | 336 | 48 | $1,258 |
| Humulin N Insulin Nph Human Isophane | 90 | 266 | 50 | $15K |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 90 | 280 | 46 | $2,178 |
| Amlodipine Besylate Generic | 85 | 258 | 44 | $970 |
| Liraglutide Generic | 57 | 65 | 23 | $34K |
Brand drugs: 838 claims; generic drugs: 1,210 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Hoa Phan were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.